Louisiana State University

LSU Digital Commons
LSU Historical Dissertations and Theses

Graduate School

1996

Synthesis of Novel Amino Acids With Incorporation Into Peptides
and Synthesis of Peptides With Novel Aggregation States.
Scott Michael Cowell
Louisiana State University and Agricultural & Mechanical College

Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses

Recommended Citation
Cowell, Scott Michael, "Synthesis of Novel Amino Acids With Incorporation Into Peptides and Synthesis of
Peptides With Novel Aggregation States." (1996). LSU Historical Dissertations and Theses. 6328.
https://digitalcommons.lsu.edu/gradschool_disstheses/6328

This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It
has been accepted for inclusion in LSU Historical Dissertations and Theses by an authorized administrator of LSU
Digital Commons. For more information, please contact gradetd@lsu.edu.

INFORMATION TO USERS

This manuscript has been reproduced from the microfilm master. UMI
films the text directly from the original or copy submitted. Thus, some
thesis and dissertation copies are in typewriter face, while others may be
from any type o f computer printer.
The quality of this reproduction is dependent upon the quality of the
copy submitted. Broken or indistinct print, colored or poor quality
illustrations and photographs, print bleedthrough, substandard margins,
and improper alignment can adversely affect reproduction.
In the unlikely event that the author did not send UMI a complete
manuscript and there are missing pages, these will be noted.

Also, if

unauthorized copyright material had to be removed, a note will indicate
the deletion.
Oversize materials (e.g., maps, drawings, charts) are reproduced by
sectioning the original, beginning at the upper left-hand comer and
continuing from left to right in equal sections with small overlaps. Each
original is also photographed in one exposure and is included in reduced
form at the back o f the book.
Photographs included in the original manuscript have been reproduced
xerographically in this copy. Higher quality 6” x 9” black and white
photographic prints are available for any photographs or illustrations
appearing in this copy for an additional charge. Contact UMI directly to
order.

UMI
A Bell & Howell Information Company
300 North Zeeb Road, Ann Arbor MI 48106-1346 USA
313/761-4700 800/521-0600

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

SYNTHESIS OF NOVEL AMINO ACIDS WITH
INCORPORATION INTO PEPTIDES AND SYNTHESIS OF
PEPTIDES WITH NOVEL AGGREGATION STATES

A Dissertation
Submitted to the Graduate Faculty of the
Louisiana State University and
Agricultural and Mechanical College
in partial fulfillment of the
requirements for the degree of
Doctor of Philosophy

in

The Department of Chemistry

By
Scott M.Cowell
B.A University of Alabama in Huntsville, 1989
December 1996

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

UMI Number: 9720342

UMI Microform 9720342
Copyright 1997, by UMI Company. All rights reserved.
This microform edition is protected against unauthorized
copying under Title 17, United States Code.

UMI

300 North Zeeb Road
Ann Arbor, MI 48103

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

Table of Contents
List of Tables...........................................................................................

iv

List of Figures..................................................................................................

v

Abstract.......................................................................................................

vii

1.1
1.2
1.3

1
1
4
4
8
9

1.4

1.5

Introduction..................................................................................
Definition of Amphipathicity and Aggregation..................
Melittin ..................................................................................
1.3.1 Discovery and Physical Properties.........................
1.3.2 Determination of structure via NMR and crystallography
1.3.3 Theories of mechanism for lytic activity of Melittin..
1.3.4 Voltage dependence and the pore mechanism
for lytic activity...........................................................
1.3.5 Effects of lipid concentration..................................
Cecropin..........................................................................................
1.4.1 Physical properties of Cecropin and analogues
1.4.2 Aggregation of Cecropin........................................
1.4.3 Voltage dependent ion channel formation..............
1.4.4 Interactions o f Cecropin with Lipid Bilayers
Modifications on Naturally occurring Peptides.........................

9
12
13
13
14
14
16
17

De Novo Peptide D esign.............................................................
Specific Peptide D esign..............................................................
Results and Discussion..............................................................
2.3.1 Solid Phase Peptide Synthesis................................
2.3.2 CD Measurements...................................................
2.3.3 Materials and Methods of Bioassay.......................
2.4
Experimental.............................................................................
2.4.1 General Methods....................................................
2.4.2 Solid Phase Peptide Synthesis.......................................
2.4.3 CD Studies.................................................................
2.5 Conclusion................................................................................

20
22
26
26
30
38
39
39
39
41
41

3.1
3.2
3.3
3.4
3.5
3.6

42
47
48
54
59
65
65

2.1
2.2
2.3

Uses of Pyrenylalanine..............................................................
Methods of Synthesis of Pyrenylalanine.................................
Synthesis of Pyrenylalanine.....................................................
Incorporation of Pyrenylalanine into a peptide.........................
CD and Fluorescent studies of pyrene containing peptide
Experimental.............................................................................
3.6.1 Synthesis of 1-bromomethylpyrene.............................
3.6.2 Synthesis of (3R,5R,6S)-4-(terf-Butoxycarbonyl)-2,3,5,6tetrahydro-3-pyrenyl-5,6-diphenyl-l,4-oxazin-2-one

ii

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

65

3.7

3.6.3 Synthesis o f (3R,5R,6S)-2,3,5,6-tetrahydro-3-pyrenyl5,6-diphenyl-l,4-oxazin-2-one...................................
3.6.4 Synthesis ofN-(l,2-dibenzyl-ethan-2-ol)-pyreny!aIanine
3.6.5 Attempted synthesis of Pyrenylalanine.........................
3.6.6 Synthesis of (2S,5R)-l-benzoyl-2-terf-butyl-5-pyenyl-3methyl-4-imidazolidinone.........................................
3.6.7 Attempted synthesis of Pyrenylalanine.........................
3.6.8 Synthesis o f Schiffbase-ferf-butoxypyrenylalanine
3.6.9 Synthesis of Pyrenylalanine.................................................
3.6.10 Synthesis ofFmoc-Pyrenylalanine.....................................
Conclusion......................................................................................

66
67
67
67
68
68
69
69
70

Bibliography......................................................................................................

71

Vita .................................................................................................................

74

iii

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited without perm ission.

List of Tables
Table 1.4.1:

Lytic Activity of Parent Peptides and Peptide Hybrids in pM
CA, CecropinA; M, Melittin; EC, Escherichia coli; PA,
Pseudomonas aeruginosa; SA, Staphylococcus aureus;
SRC, sheep red blood cells.............................................................. 19

Table 2.3.1:

Relative Molar ellipticities and % a-helicities for (KALKALK)},
(KLAKKLA)j, and (KLAKLAK)}.....................................................34

iv

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

List of Figures
Figure 1.2.1: Side view of an amphipathic a-helix P represents polar residues
while N represents nonpolar residues............................................

2

Figure 1.2.2: Longitudinal view of an amphipathic a-helical peptide
where P represents polar face while N represents nonpolar
face.................................................................................................

2

Figure 1.2.3: Representation of an aggregated amphipathic a-helical peptide in
an aqueous environment P represents Polar residues while N
represents Nonpolar residues.........................................................

3

Figure 1.2.4: Representation of the amphipathic a-helical peptides in a membrane
environment. P represents Polar residues while N represents nonpolar
residues....................................................................................
5
Figure 1.3.1: Edmundson Helical wheel of Melittin............................................

7

Figure 1.3.2:

Mechanism for Melittin pore formation via the “pore” method

10

Figure 1.3.3:

Mechanism of Melittin “rafting” formation.................................

11

Figure 1.4.1:

Edmundson Helical wheel of Cecropin A....................................... 15

Figure 2.1.1: Two amphipathic structures generated by the heptads sequence The
left figure represents a 160° polar face while the right figure
represents a 180° polar face....................................................
23
Figure 2.2.2:

Edmundson wheel of (Lys,Leu,Ala,Lys,Leu,Ala,Lysi....................25

Figure 2.2.3:

Edmundson wheel of (Lys,Ala,Leu,Lys,Ala,Leu,Lys).....................27

Figure 2.2.4:

Edmundson wheel of (Lys,Leu,Ala,Lys,Lys,Leu,AIa).....................28

Figure 2.3.1:

CD spectra of (Lys,Ala,Leu,Lys,Ala,Leu,Lys)................................32

Figure 2.3.2:

CD spectra of (Lys,Leu,AIa,Lys,Lys,Leu,Ala^................................35

Figure 2.3.3:

CD spectra of (Lys,Leu,Ala,Lys,Leu,Ala,Lys^............................

36

Figure 2.3.4

Log [Peptide] vs. Molar EUipticity of all the peptides..................

37

Figure 3.1.1: Pyrenylalanine................................................................................ 43

V

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout p erm ission .

Figure 3.2.1:

Synthesis of racemic pyrenylalanine............................................... 49

Figure 3.2.2:

Synthesis o f pyrenylalanine with resolution......................................50

Figure 3.2.3:

Synthesis of Pyrenylalanine via enantioselective hydrogenation

Figure 3.3.1:

William’s glycine template............................................................... 53

51

Figure 3.3.2: Alkylation backside attack via glycine template.............................. 53
Figure 3.3.3: Attempted Synthesis of Pyrenylalanine using
William’s glycine template................................................................ 55
Figure 3.3.4: Seebach’s glycine template......................................................... 56
Figure 3.3.5: Alkylated Seebach’s glycine template demonstrating how NOES Y
interactions are used to check the enantioselectivity of the reaction. 56
Figure 3.3.6: Attempted synthesis of Pyrenylalanine using
Seebach’s glycine template........................................................ 57
Figure 3.3.7: Synthesis of Pyrenylalanine viaO’Donnel’s glycine template

58

Figure 3.5.1: Absorbance spectra of labeled peptide............................................ 61
Figure 3.5.2: CD spectra of labeled peptide..................................................... 62
Figure 3.5.3. Emission spectra of labeled peptide 1 M NaCl..........................

63

Figure 3.5.4: Emission spectra of labeled peptide 0 M NaCl................................ 64

vi

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

Abstract
Peptides exhibit properties based on the amino acids present in the peptide and
structure the peptide assumes in its environment. For example, peptides have been
shown to be antimicrobial when they are amphipathic and in an a-helical shape. The
mechanism for this antimicrobial activity is subject to dispute. One theory states that
the peptides work by forming a “pore” through the cell membrane which causes a
depolarization of the membrane and the cell lysis because of osmosis. Another theory
states that the peptides merely compromise the integrity of the membrane by
solubilizing the membrane.
In order for the “pore” theory of lytic activity to occur, the peptides must arrange
themselves in a discrete aggregated fashion. The goal of this research is to explore the
nature of the aggregated state of designed peptides through the use of CD spectroscopy
and fluorescent labeling.
Several peptides were designed using a minimalist approach and were measured
using CD spectroscopy to explore how the placement of leucines in the peptides cause a
change in their propensity for aggregation. Using this information, the site for an
incorporation of a fluorescently labeled peptide was chosen.
The synthesis of the fluorescently labeled amino acid presented an opportunity to
explore different types of glycine templates and to find a quicker method for making
the amino acid in high yields. After the synthesis of the amino acid, it was incorporated
into the peptides and CD and fluorescence studies were accomplished. The result shows
the peptides, when aggregated, align themselves in an antiparallel fashion.

vii
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1.1 Introduction
The use of antibiotics has caused a general increase in the good health of the
people o f the world. However, the microbes for which these antibiotics are intended
have been slowly building resistance. This has caused a general alarm in the medical
field and has spurred research into finding alternatives to the traditional antibiotics. One
such alternative has been the use of lytic peptides which can selectively destroy
microbes. However, the mechanism by which they destroy pathogens is in dispute.
This thesis will attempt to explain the mechanism o f interaction while designing novel
lytic peptides for possible drug use.
1.2 Definition of Amphipathicity and Aggregation
Some peptides possess the ability to be amphipathic when in an a-helical form.
An amphipathic a-helix has all the polar residues aligned on one side of the a-helical
axis.

Figure 1.2.1 shows a side view of an amphipathic peptide in an a-helical

conformation while Figure 1.2.2 shows a longitudinal view of an amphipathic a-helix.
Amphipathic peptides may aggregate. This is best described with this idea of
solubility. In an aqueous environment, an amphipathic peptide will want to associate,
or aggregate, with another peptide in order for the nonpolar residues of the peptides to
solubilize one another. In the case of an aqueous environment, the nonpolar portion of
the peptide will be sequestered within the peptide aggregate while the polar portions
will be sequestered on the exterior of the peptide aggregate. Figure 1.2.3 shows four
amphipathic a-helical peptides aggregated in an aqueous environment.

l
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Figure 1.2.1: Side view of an amphipathic a-helix P represents polar residues
while N represents nonpolar residues

Figure 1.2.2: Longitudinal view of an amphipathic a-helical peptide where
P represents Polar residues while N represents Nonpolar residues
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Figure 1.2.3: Representation of an aggregated amphipathic a-helical peptide in an
aqueous environment P represents Polar residues while N represents Nonpolar residues
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An analogous peptide aggregate can form in a membrane. If four peptides aggregate in a
membrane, all the positive charges are on the inner part of the assembly while the
nonpolar residues of the peptides interact with the nonpolar regions on the membrane.
Figure 1.2.4 represents four peptides aggregating in an membrane environment where P
represents polar residues and N represents nonpolar residues. This is one theory which
addresses the lytic properties o f an amphipathic peptide. The peptide's polar 'inner circle'
provides an aqueous environment which can span the hydrophobic part of the
membrane.

The aqueous environment allows water and ions to freely flow to the

cytoplasm of the cell, depolarizing the membrane and causing the cell to rupture.
Because of the ability of amphipathic peptides to lyse cells, nature uses them as part of
noncellular immune response. Two of these types of peptides discovered are Melittin
and Cecropin.
1.3 Melittin
1.3.1 Discovery and Physical properties
Melittin, a lytic peptide isolated from the venom o f the bee Apis mellifera*,
consists of 26 amino acids with a highly basic C-terminus region with a net charge of 6+
and a hydrophobic N-terminus region. It contains four separate parts: N-terminus aheix, the flexible “hinge” region, the central a-helix and the positively charged Cterminus region2.
When in an a-helical shape, melittin has the property of amphipathicity; the
polar region will align mostly on one side of the peptide while the nonpolar region will
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Figure 1.2.4: Representation of the amphipathic a-helical peptides in an membrane
environment. P represents Polar residues while N represents nonpolar residues
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be on the opposite side of the side of the peptide (see figure 1.3.1). This is not perfectly
longitudinal due to the proline-14 located in the center of the peptide. The proline-14
causes a bend in the peptide due to the structure of the amino acid hence the “hinged”
region of the peptide.
The amphipathicity of melittin causes the peptide to demonstrate certain
properties1. Melittin is soluble in aqueous solutions. This solubility causes the
hydrophobic region of the amphipathic peptide to aggregate into a tetrameric form. The
proximity of the positive charges from the lysines in this self-associated state results in
a natural repulsion to self-association. The contribution of charge repulsion in an
aggregated peptide, when the charge is increased from +4 to +6 by varying ionic
strength, is about 600cal/(charge*mol of tetrameric melittin)3. Aggregation can be
promoted, or inhibited in melittin by exploiting these contradictory properties.
Anything which suppresses charge formation on the lysine side chains promotes
aggregation of

the peptides.

Solutions with increasing ionic strength promote

aggregation by providing a counterion for the (+) charges on the lysines which
effectively screen the charge.1 The nature of the counterion is also a factor in the
aggregation of melittin. It has been found that the use of a divalent ion, such as Na2S0 4 ,
is more effective at promoting aggregation than univalent salts4. With the use of
Na2SC>4, Schwarz explored the nature of the formation of tetramers using stop-flow
techniques and found that dimerization was the slow step in aqueous self-association,
while dimer-dimer interactions to form tetramers were diffusion controlled4. However
the use of multivalent ions is questioned since multivalent ions form tight interactions
with the peptide which are not compatible with helix formation5.
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Figure 1.3.1: Edmundson Helical wheel of Melittin
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Aggregation is also promoted by changing the pH

By increasing the pH o f the

aqueous solution, the lysine side chains are deprotonated, reducing charge and
promoting aggregation. Since melittin has three s-amino [Lys-7, Lys-21, Lys-23] and
two E-guanidine [Arg-22, Arg-24] titratable groups, the stepwise titration has been
reported.5 The ionic strength of a solution factors into the influence of the pH on
melittin. It has been found that there are two stepwise alkaline transitions when melittin
starts at low ionic strength and three at high ionic strength.
A study was also done to explore the charge type vs. a-helicity of the melittin.
In one case, a negatively charged analogue of melittin was synthesized and the ahelicity of the melittin analogue was then measured in varying pH, ionic strength and
temperature CD studies.6 A marked decrease in the a-helix propensity of anionic
melittin was noted in all conditions. The authors postulated that this was due to the fact
that negative charges were in closer proximity compared to the analogous positive
charges on melittin. This therefore increased the helix-breaking propensity of the polar
region of melittin.6
1.3.2 Determination of structure via NMR and crystallography
The structure of melittin was determined by high-resolution NMR spectroscopy.
In methanol it was found to adopt an a-helical monomeric form.1 This study also
showed that there was a relaxation of the a-helicity around the Leu-13-pro-14 region
due to the ‘bending’ nature of the proline. The regions of a-helicity had characteristic
NOE’s while it was noted that towards the end of the peptides, the NOE’s were not as
prevalent. The conclusion was that the a-helicity of melittin was more relaxed at the
ends than in the center of the peptide with the exception of the region that contains the
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proline. Melittin was also crystallized in an medium o f high ionic strength and the X-ray
crystal structure was solved. Under these conditions,

melittin adopts an a-helical

conformation.1
1.3.3 Theories for the mechanism of lytic activity o f Melittin
The mechanism of hemolytic activity of melittin is subject to debate. One theory
suggests that melittin binds to the surface of a membrane. It then buries into the surface
of the membrane through hydrophobic interaction. When four peptides are similarly
buried and in proximity to one another, it forms a transmembrane pore which causes
lysis via depolarization of the membrane and subsequent osmotic pressure. Figure 1.3.2
illustrates this mechanism.
Another theory about the hemolytic activity of melittin is that the membrane
permeability of the peptides cause destruction by micellization of patches of the
membrane.1 This is similar to detergent solubilization. The binding of the peptide and
burying of the peptide into the membrane is similar to that of the pore formation theory.
Figure 1.3.3 illustrates this mechanism. Evidence for both theories will be presented in
the following sections.
1.3.4 Voltage dependence and the pore mechanism for lytic activity
Melittin shows evidence of a pore formation in a membrane with an applied
voltage gradient.1 The application of a potential across a membrane in the presence of a
critical concentration of melittin shows a depolarization of the membrane caused by Na+
ion permeability. Depolarization of the membrane increases in a stepwise fashion as the
fourth order of melittin concentration.

This indicates that the melittin is coming

together in a tetrameric form l.

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

10

Figure 1.3.2: Mechanism for Melittin pore formation via the “pore” method
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Figure 1.3.3: Mechanism of Melittin “rafting” formation

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

1.3.5 Effects of lipid concentration
The binding efficiencies of melittin to different types of membranes have also
been studied. Many studies have been done on the nature and binding affinities of
melittin to various micelles and membranes. Because of the amphipathicity of melittin,
the hydrophobic region of melittin interacts with the lipid membrane. Membranes tend
to promote a-helical secondary structure in melittin through hydrophobic interaction
and melittin was found to bind to a membrane as a monomer.1 The binding of melittin
to a membrane was studied as a function of pH and it was determined that binding
increased at increased pH.7 Increased pH decrease the amount of charge on the lysines
causing easier binding to the membranes.
Studies have been done to determine the orientation of the peptide in a
membrane after it has bound to the membrane. Determining the orientation of melittin
by fluorescence of the tryptophan showed that the tryptophan orientation existed to two
forms: it was either embedded in the hydrophobic membrane close to the phospholipid
headgroups, or it was exposed to the solvent system8.
The binding efficiencies of melittin to phophatidylglycerol/phosphatidylcholine
membrane showed that there is a greater binding efficiency to this membrane due to
presence of negative charges on the membrane 9. Melittin, in this type of membrane,
also reoriented it. The presence of extra negative charge in the membrane caused the
N+ charges of the phosphatidylcholine to orient towards the hydrophobic regions. The
addition of melittin caused the N+ charges to reorient towards the aqueous media. This
is found in the addition of melittin to phosphatidylcholine membranes. Melittin was
also introduced to membranes which contain unsaturated tail groups 10. It was found

p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout perm ission.

that there was a faster leakage of contents in the membrane containing unsaturated
bonds. The authors speculated that was not due to the nature o f the membrane, but
because of the perturbation of the melittin in the membrane. Binding studies of melittin
were also done on reversed micelles lI. Again it was found that melittin binds to the
hydrophilic surface of reversed micelles and that it binds in a monomer form.
The binding of melittin caused leakage of the membranes without the presence
of a voltage gradient at lytic concentrations is evidence that lytic activity could be
caused by the solubilization o f the membrane.
1.4 Cecropin
1.4.1 Physical properties of cecropin and analogues
Cecropin A, a peptide isolated from the Hylophora cecropia moth, acts as the
moth's immune system 12. The same moth contained cecropin-like peptides subsequently
named cecropin B 13 and cecropin D 14 which Merrifield synthesized by via solid phase
peptide synthesis. Merrifield first synthesized a fraction of the cecropin A peptide
consisting of the first 33 residues. 15 This synthetic peptide proved only slightly less
effective as an antimicrobial peptide than the full length peptide.
All the cecropins share certain similarities. They consist of 31 and 39 amino
acids, have strongly basic hydrophilic regions near the N-terminus and hydrophobic
regions near the C-terminus.13 These two regions are separated by a central part that
contains the a-helix breaking sequence of glycine and proline. An Edmundson helical
wheel of Cecropin A, consisting of 37 amino acids is shown in figure 1.4.1. The
structure of the peptides were determined by NMR and CD to have a-helical character
in 15% HFIP.'6
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A cecropin analogue has also been isolated in mammals. The analogous peptide,
named cecropin PI, was isolated from pig intestine. Because of this discovery, Boman
theorizes that cecropin like peptides may be present in other mammals as a means of
regulating bacterial growth in animals.17 Though analogous to the other cecropins,
cecropin PI does not contain the central a-helix breaking sequence of glycine and
proline common to the other cecropins.18
1.4.2 Aggregation of Cecropin
Cecropins has an amphipathic a-helical structure with the polar region
containing predominantly positive charges. Consequently hydrophobic interactions of
the a-helix promotes aggregation in neutral conditions, electrostatic repulsion of likecharged amino acids diminish aggregation. Therefore the use of any system, whether
pH, ionic strength or fluorinated solvents, that suppresses the charge associated with the
peptide and will promote the formation of aggregated peptides. This has been
determined with cecropin by CD and ESR 19. Cecropin AD, a hybrid of cecropin A and
cecropin D, aggregated in the presence of 5-10% (v/v) HFIP. The researches also
showed that increasing the concentration o f cecropin in 5-10% HFIP does not increase
aggregation. Moreover, decreasing the concentration in the above conditions does not
have any effect on the monomer- aggregate equilibrium19. The peptides also exhibited
aggregate formation in the presence of high salt concentration (1.0 M NaCl) and high
p H 15.
1.4.3 Voltage dependent ion channel formation.
Cecropin, at antimicrobial concentrations, formed channels through planar lipid
membranes with a negative potential across the membrane. Channel formation is
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Figure 1.4.1: Edmundson Helical wheel o f Cecropin A
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decreased in analogous peptides which do not have the hinged region present 20. The
authors suggest that the insertion of the hydrophobic region of the amphipathic peptide
and subsequent channel formation is dependent on the hinged region of the peptide.
However the central hinged region is not necessary for lytic activity since it is not
present in cecropin P I18.

Molecular modeling found that cecropin possesses the

possibility o f two types of transmembrane pores 21. Without an applied potential, the
predicted pore forms with the nonpolar C-terminus buried in the lipid bilayer while the
hydrophilic N-terminus is associated with the phospholipid headgroups. While with an
applied potential, the ion channel is formed with the hydrophilic N-terminus group
actually forming the channel. This hypothesis is not supported by experimental data.
1.4.4 Interactions of Cecropin with lipid bilayers
The controversy over the mechanism of action of lytic activity, by pore
formation or membrane permeability, exists for cecropins. The cecropins seem to bind
to a lipid bilayer as a monomer. Cecropin B2, a cecropin derivative isolated from the
silkworm Bombyx moris, supposedly causes disintegration of the membrane leading to
membrane permeation22. This was determined by the use of spectroscopic dyes placed
on the cecropin B2. The concentration of cecropin needed to lyse the liposome can be
correlated with the amount needed to lyse a bacteria and it was concluded that cecropin
coats the bacteria before lysis occurs [Merrifield, 1988 #157]. However, the study was
done on neutral liposomes. It is possible that on a neutral membrane, the action
involving membrane permeation is possible while on a membrane containing a distinct
potential, the pore formation is predominant.
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1.5 Modifications on naturally occurring peptides
The use o f Cecropin as a possible antibiotic proves to be cost prohibitive due to
the length of the peptide. Melittin, on the other hand, is smaller and less costly to
produce, but its property of lysing erythrocytes makes it useless as a drug. Therefore
scientists have experimented with hybrids in order to combine the broad spectrum
antibiotic character of the cecropins with the shorter length o f melittin while trying to
suppress melittin’s property of lysing erythrocytes.
One o f the first hybrids synthesized was the combination o f Cecropin A and
Cecropin D 23. This consisted of combining the amino acids 1-11 of cecropin A with
amino acids 12-37 of Cecropin D. From this study, Fink and coworkers confirmed the
importance of the highly basic amphipathic a-helix have in the antimicrobial activity.
With this, more ambitious hybrids were made in order to decrease the size of the
peptides.
The first highly successful peptide hybrid combined the basic residues of
cecropin A (1-13) with the hydrophobic residues of melittin (1-13) 24. The result was
better antibacterial activity compared to the parent peptides even when their overall size
was decreased to 26 amino acids which represents a 30% decrease compared to
cecropin24. Figure 1.5.1 shows a table comparing the antimicrobial activity of the parent
peptides with various hybrids of cecropin and melittin. The authors were trying to
follow the basic structural components found in the lytic peptides which are a basic
amphipathic a-helix, a flexible segment between helices and a hydrophobic a-helix24.
Manipulation of the peptide sequence showed that the removal of the Gly Pro hinge
region caused an overall increase in bioactivity24. The NMR showed that the peptide
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forms an a-helical structure25. Throughout the studies, the authors assumed that the
mechanism for lytic activity was due to pore formation. They then concluded that the
minimum length for the peptide to span the membrane was 20 amino acids long. This,

however, was soon proven false.
The authors continued to do research on the CA(1-13)M(1-13) peptide. By
deleting amino acids from the hydrophobic melittin like region of the hybrid, they
showed that even 15 amino acid peptide hybrids have lytic activity26. This finding
caused a revision of the theory of pore formation as the mechanism of action in the
peptide. It is interesting to note the CD studies done on these peptides. Merrifield
showed that the peptides that were 18 and 20 amino acids long contained some 0sheeting in 4-12% HFIP with a plateau o f 50% helicity at 16-20% HTTP. The small
peptides were observed to have a high a-helix content at only 12% HFIP. This was
attributed to the absence of the Gly-De-Gly-Ala which disrupts the helix continuity25.
With these findings,

the authors decided that pore formation may be

accomplished by noncovalent dimerization of the peptides to span the membrane or
through a 3io-helix formation25.
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Table 1.4.1: Lytic Activity of Parent Peptides and Peptide Hybrids in pM CA,
CecropinA; M, Melittin; EC, Escherichia coir, PA, Pseudomonas aeruginosa; SA,
Staphylococcus aureus; SRC, sheep rec blood cells
EC
Parent Peptides
PA
SA
SRC
0.2
Cecropin A (1-37)
4
>200
>200
Melittin (1-26)
0.8
0.2
0.2
4-8
Hybrid Peptides
CA(1-24)M(1-13)
0.3
0.5
6
>200
CA(1-13)M(1-13)
0.5
0.7
2
>200
CA(25-37)M(1-13)
200
20
>300
>300
M(1-13)CA(1-13)
1
0.3
5
80
0.7
0.7
M(16-26)CA(1-13)
10
>200
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2.1 De Novo Peptide design
Studies have shown that sequence homology is not prerequisite for biological
activity as long as the peptide remains amphipathic and is of sufficient length 21.
Simplified analogs of natural peptides that retain or enhance helix amphipathicity and
“minimalist” de novo designed amphipathic helix peptides have lytic activity28. The

purpose of the research accomplished was to design antimicrobial peptides using a
“minimalist” approach. The goal was to incorporate features found in nature with
recent advances in de novo design to form peptides that were both antimicrobial and
gave information concerning the mechanism of interaction of the peptides. The design
of the peptides were based on the “pore” theory of their mechanism in which the lytic
activity of the peptides occurred due to the formation of a pore across the membrane
which depolarizes the membrane and causes subsequent lysing. In order for this to
occur, in our design structure, one had to make the peptides so that they possessed the
possibility to aggregate in a certain fashion. Hence the peptides had to be amphipathic
when in an a-helical structure and leucines were used in the hydrophobic region to
ensure that aggregation could occur.
An aspect of the design actively explored was the role of the hydrophilic face of
the peptides. This was based on the idea that the degree arc of the hydrophilic face
could affect how the peptides would aggregate in a membrane. By having a large
degree arc, one would expect a larger pore to form while having a smaller degree arc,
one would have a smaller pore form. If the actual size o f the pore could not be affected,
then the ease of aggregation of the pore could be affected by the amount of nonpolar
moiety present in the system.

20
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Another aspect of the antimicrobial peptides was explored concerning the idea of
a leucine zipper. Leucine zippers would be used to facilitate the aggregation of the
peptides in aqueous environment. With the peptides aggregated into discrete packages
in aqueous environment, one could think of this as a form of delivering the peptides to
cells in “packages”. After initial binding to the cell membrane, the peptide tetramers
would then quickly rearrange to a pore formation and lyse the cell. Hence, if the pore
model is correct, the peptides would act as their own drug delivery system and less
peptide would be needed in order to facilitate a lytic and thus antimicrobial response.
Finally, the peptides were designed in a minimalistic fashion so that, if their use
as a drug was possible, the peptides would be easy to mass produce through solution
phase synthesis. The peptides were designed as heptad repeats. Heptad repeats have the
ability to form descreet amphipathic units while making them easier to produce with
solution phase chemistry. Therefore we designed putative lytic peptides consisting of
heptad repeats by subdividing the heptad into two identical trimers and an additional
residue. To keep the polar and nonpolar faces approximately the same size there are
two possibilities:

design trimers made from two nonpolar residues, N, and one

positively charged residue, P, with an additional positively charged residue, P; or
trimers made from one N, two Ps and an additional N. There are nine possible and eight
unique combinations of heptads for each of these possibilities. The heptads composed
with trimers N,N and P with a P are: (PNN)(PNN)P, (PNN)P(PNN), P(PNN)(PNN),
(NNP)(NNP)P,

(NNP)P(NNP), (NPN)(NPN)P, (NPN)P(NPN), and P(NPN)(NPN).

The latter three heptads are not amphipathic in a-helical conformations and so were not
considered further. The peptides that were designed and synthesized can be generalized
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as (PNN)(PNN)P and (NNP)P(NNP). This design approach generates a large number of
structurally related peptides that differ only in the sequence or that have similar
sequences with single amino acid residue replacements at several related sites in a
peptide. Figure 2,1.1 shows the two distinct amphipathic peptides generated by the
above sequences. These peptide designs encompass all the aspects that was desired
which were to be minimalistic and have distinct parameters.

The change in the

sequence of the designed heptad changed the polar face of the peptdes. This was a
source of experimentation to see if the degree-arc o f polar face would change the
biological activity of the peptides. Finally, the face of the nonpolar aspect of the
molecule provided a site for possible aggregation.
2.2 Specific Peptide Design
The amino acids incorporated in the P and N o f the above de novo design system
were leucines, lysines and alanines. Leucines were used to provide a possible site for
aggregation of the peptides. The lysines provide a positively charged amino acid which
would be easily incorporated into a peptide and would be easily used on a solid phase
peptide synthesis. Finally, the alanines were incorporated because of their ability to
promote a-helicity.
The

first

peptide

designed

consisted

of

a

heptad

of

(Lys,Leu,Ala,Lys,Leu,Ala,Lys) repeated three times. It was designed to be a 21 residue
peptide in order to assure that it would span a membrane and obtain an a-helical
structure under appropriate conditions.
By definition, a leucine zipper can occur when leucines are placed in every
seventh position on a peptide chain.

Following this rule, the peptides designed will be
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(PNNPNNP)
(PNNPPNN)
Figure 2.1.1: Two amphipathic structures generated by the heptad sequences. The left
figure represents a 160° polar face while the right figure represents a 180° polar face
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capable of forming leucine zippers. The primary leucine zipper has three leucine amino
acids spaced so that they will have the ability to aggregate easily. When a peptide
assumes an a-helical conformation, it is usually the core of the peptide that will be most
helical, while the ends of the peptide will have more random coil character. Therefore,
the leucines in the core of the peptide will form a more stable aggregated state and are
thus defined as the primary positions. The other leucines, called the secondary system,
are four amino acids away from the primary system and help to stabilize the leucine
zipper by providing additional hydrophobic character. Figure 2.2.2 represents the
Edmundson wheel of this particular peptide. This peptide shows a 180° polar face with a
possible leucine aggregation site.
Another peptide was designed to determine whether the peptide activity was
sequence dependent. The sequence is (Lys,Ala,Leu,Lys,Ala,Leu,Lys)3 and is very
similar to the first sequence presented in this section, another. Consequently the leucine
zippers in the primary state will be closer to the lysine polar face of the peptide. The
peptide with a 180° polar face is shown figure 2.2.3.
Finally

another

design

(Lys,LeuvAla,Lys,Lys,Leu,Ala).

consisted

of

the

heptad

sequence

of

This demonstrates that by merely changing the

sequence of the amino acids, the peptide can have a different polar face in the a-helical
structure. In this case, the leucine zipper in the primaiy position are still adjacent to the
lysine polar face of the peptide. The peptide has a 160° polar face and figure 2.2.4
shows the Edmundson helical wheel of the peptide.
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2° Positions
JLeu.

£ys

eu

Leu
1° Positions

Lys
Lys>
Ly^

Ala

Lys.

Figure 2.2.2: Edmundson wheel of (Lys,LeurAla,Lys,Leu,Ala,Lysj
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To conclude, the peptides were designed to show how changes in the sequence
homology of the peptides changes some basic characteristics. All peptides designed in
this section have common characteristics. First, they all are designed in the minimalist
fashion with the same amino acids used in each peptide and all amphipathic when in an
a-helical conformation. They also have the ability to aggregate in a descreet fashion
using a phenomena called a leucine zipper. The difference in these peptides result from
changes in the sequence homology of the peptides. Due to the changes in the sequence,
two peptides have a 180° polar face while the third has a 160° polar face.
2.3 Results and Discussion
2.3.1 Solid Phase Peptide Synthesis
The peptides were all synthesized using a Milligen 9050 peptide synthesizer. As
opposed to solution phase peptide synthesis, which couples dipeptides and tripeptides
into larger ones, solid phase peptide synthesis couples individual amino acids
sequentially in order to form the larger peptide.
Solid phase peptide synthesis uses a solid phase support which is covalently
attached to the first amino acid. This anchors the first amino acid as the others are
coupled to it sequentially. In this case, polystyrene beads with a polyethylene glycol
chain, known as PAL-PEG-PS resin, was used as the solid phase support. The first
amino acid is coupled to the resin via an amide link. The amino acids which follow are
protected amino acids. The amino acids can have a variety of different protecting
groups associated with them. In this methodology, the a-amine on the amino acids were
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1° Positions
Figure 2.2.3: Edmundson wheel o f (Lys,Ala,Leu,Lys,Ala,Leu,Lys3
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Figure 2.2.4: Edmundson wheel of (Lys,Lue,Ala,Lys,Lys,Leu,Alaj
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protected using fluorenylmethoxycarbonyl (FMOC) while the 8-amine, in the case of the
lysine, was protected with tert-butyloxycarbonyl (t-BOC). Two separate protecting
groups are used because each protecting group is removed under different conditions,
amines protected by FMOC are removed by a base, namely 20% piperidine, while the
amines protected by t-BOC are removed by trifluoroacetic acid.

These are called

orthogonal protecting groups. By using this method, it is possible to deprotect the ex
amine while still leaving the 8-amine protected. Finally, the carboxy portion of the
amino acid is activated as a pentafluorophenol (Opf) ester.
The sequence of synthesis is as follows. The first amino acid is placed on the
Pal-Peg-PS resin via an amide bond. The linked amino acid is then deprotected by a
piperidine wash and the next amino acid is linked to it. This cycle is repeated until the
desired peptide is made. After the peptide is made, the peptide is cleaved off the resin
using TFA. The TFA also deprotects the t-BOC which protected the e-amine of the
lysines. The peptide was purified by two separate methods. Originally the peptides
were deprotected using a cleavage cocktail called Reagent B (8.8 mL triflouroacetic
acid, 0.5 mL phenol, 0.5 mL water, 0.2 mL of triisopropylsilane). After stirring, the
peptide was precipitated out of the cocktail by slowly pouring the peptide/cocktail
solution into cold diethyl ether. The purified peptide was centrifuged into a pellet and
allowed to dry. The peptide was dissolved in 20% acetic acid and passed through a
Sephadex G-15 column to remove any residue of the cleavage cocktail and any very
small peptides.
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Another method which was employed to purify the peptide was to directly
dissolve the peptide/cleavage cocktail in 20% acetic acid and extract the solution in
diethyl ether. The 20% acetic acid solution is frozen and lyophilized. The purpose of
the diethyl ether extraction was to remove any of the nonpolar organics from the
cleavage cocktail. This method also eliminated the need to pass the peptide through a
Sephadex G-15 column. Both methods were employed during the synthesis phase of the
research and worked equally well.
Due to the nature of solid phase synthesis, if an individual peptide was not
successfully deprotected, then there could be failed coupling of the next amino acid.
These were separated using RP-HPLC and all three peptides were purified using a RPHPLC with a C-4 column. The mobile phase was a gradient consisting of water and
acetonitrile. Both mobile phases had 0.5% TFA added to insure no bacterial growth and
to buffer the solution. Once the conditions of purification were determined and the
retention times were noted, a large amount of peptide, approximately 30 mg, was
purified using a semi-preparatory C-4 column. A fraction o f the purified peptide was
rechecked using a C-18 analytical column. Plasma desorption mass spectroscopy was
performed to determine if the correct peptide was synthesized.
2.3.2 CD Measurements
A CD study was performed on the peptides to determine the structure as a
function of concentration. This study did not use any salt, pH changes, or SDS micelles
or vesicles to effect the formation of secondary structure. The study was conducted on
the peptides to determine if the influence of the nonpolar portions of the amphipathic ahelix would enforce the a-helix by overcoming the repulsive forces of the charged
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amino acids on the peptides. If this was indeed the case and shows how the change in
the sequence homology effects helix formation in the peptide.
Of the three peptides, (LySjAlajLeuXysAlaJ^eu^Lys^ gave the smoothest
transition from a random coil to an a-helical shape. The a-helical CD spectrum is
characterized by m in im a at 208 and 222 nm while random coil has an m in im a at around
200. If a peptide is going from a random coil to an a-helical secondary structure, then
all the CDs o f this transition will pass through one point when layed on top of one
another. This is called the isodichroic point and is shown in figure 2.3.1.
CD raw data is reported in millidegrees,

m e a n in g

the degree the polarized light

is shifted after it interacts with the peptide. In order to facilitate interpretation, the data
is converted to molar ellipticity. This number represents the change in the degree of
polarized light per mol of peptide residue. Molar ellipticity is usually calculated at
222nm wavelength of light. This is done using the following formula:
[0 ]222=

100*

(milidegreesl^
1000 * C * L

Where: C= concentration of peptide per residue (Mol)
L= Pathlength of the cell (cm)
After molar ellipticity is determined, % a-helicity for each peptide is determined
using the following formula:
% a-helicity = 100* ( 161777 + 3000)
33000

With the above formulas, a table 2.3.2 is generated showing the different molar
ellipticities and % a-helicities for each peptide studied.
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Figure 2.3.1: CD spectra of (Lys,Ala,Leu,Lys,Ala,Leu,Lys3

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

33

Both (LysvLeuvA.la,LysJLys,LeaAla)3 and (Lys,LeuvAiaXysXeuvA.la,Lys)3 had
similar transitions until the peptide concentration approached log 0.9 to 1.0. The peptide
(Lys*AJaXeu,Lys,AlaJLeuJLys)3 also had the highest molar ellipticity of -24,887.26 at a
log of 1.113 (12.97 mM). The peptide (Lys,LeuAla,Lys,Leu,Ala,Lys)3 has a molar
ellipticity

of

-20,101.74

at

a

log

of

1.063

(11.56

mM)

while

(LysJJeuAla,Lys,LysJLeurAla)3 demonstrated the least propensity of aggregation with a
molar ellipticity of -14,249.65 at a log of 1.15 (14.125 mM). Figures 2.3.3 and 2.3.4
represent

the

CD

spectra

of

(Lys,LeurAia,Lys,Lys,Leu,Ala)3

and

(Lys,Leu,Ala,Lys,Leu,Ala,Lys)3. Figure 2.3.5 represents a comparison of the molar
ellipticity vs. the log of the concentration of the three peptides.
The two peptides which demonstrated the greatest difference in propensity for ahelicity are (Lys,Leu,Ala,Lys,Lys,Leu,Ala)3, and (Lys,Leu,Ala,Lys,Lys,Leu,Ala)3. It is
interesting to note that by merely changing the sequence of the amino acids, the
propensity for a-helicity is dramatically changed. The explanation for this lies in how
the peptides become a-helical.

When a peptide is said to be in an a-helical

comformation, this doesn’t mean that all amino acids are participating equally in the ahelix. In fact, as demonstrated by melittin, the ends o f the peptide still stay in a random
coil conformation. a-Helicity does not actually start until the third residue of the
peptide. The peptide (Lys,Ala,Leu,Lys,AlaXeu,Lys)3 has the highest propensity for
aggregation due to the primary leucine zipper. As shown on figure 2.2.3, the primary
leucine zipper for this peptide starts are on residues 3, 10 and 17. Therefore all o f the
leucine amino acids are within the a-helical portion o f the peptide and can equally
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Table 2.3.1: Relative Molar ellipticities and % a-helicities for
(KALKALKfc, (KLAKKLAb, and (KLAKLAK)?
(KALKALK)3
Log [Peptides] mM
0.3784
0.5545
0.6794
0.7763
0.8585
0.9557
0.9836
1.035
1.081
1.113

Molar Ellipticity
1957.163
2426.919
5899.582
8584.43
13500.99
16674.05
21367.48
23117.42
24700.6
24887.26

% a-Helicity
15.022
16.445
26.968
35.104
50.003
59.618
73.841
79.144
83.507
84.507

(KLAKKLA)s
Log [Peptides] mM
0.40926
0.58535
0.7103
0.80787
0.9212
0.98399
1.0120
1.0630

Molar Ellipticity
954.4222
4687.674
7427.718
7939.197
13121.68
14293.2
16749.12
20101.74

% a-Helicity
11.9831
23.296
31.599
33.149
48.8536
52.404
59.8458
70.0052

(KLAKLAK>3
Log [Peptide] mM
0.449
0.625
0.769
0.849
1.025
1.104
1.150

Molar Ellipticity
1689.359
2873.4
5019.697
5570.235
12088.52
14171.35
14249.65

% a-Helicity
14.210
17.798
24.302
25.970
45.723
52.034
52.272
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Figure 2.3.2: CD spectra of (LySjLeu^AlajLySjLySjLeu^Ala^
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participate in the aggregation of the peptide. In contrast, the primary leucine zipper for
(Lys,Lei^Ala,Lys,LeuvAJa,Lys)3, the leucines for the primary zipper are located on
residues 2, 9, 16. The leucine on residue number 2 is not in an a-helix conformation
and

therefore

does

not

participate

in

a

leucine

zipper.

The

peptide

(Lys,LeivYla,Lys,Lys,LeuA.la)3 also has the primary leucine zipper located on the 2, 9
and 16 residue. The greater tenacity of this peptide for aggregation is due to the 160°
polar face. Any type of aggregation is helped with nonpolar residues. The greater the
face of nonpolar residues, the greater the propensity for nonpolar-nonpolar interactions.
2.3.3 Materials and Methods of Bioassay
All bioassays were done by Martha Juban. Purified peptides were assayed for lytic
activity against ATCC strains of Escherichia coli 25922, Pseudomonas aeruginosa
27853 and Staphylcoccus aureus 29213.

Minimum inhibitory concentrations were

determined by the broth microdilution method outlined for aerobic bacteria in NCCLS
Document M7-A2, second edition.
Peptide solutions were prepared as a serial 2:1 dilutions from a 512 |ig/mL to 2
pg/mL. Bacterial cultures were grown to mid-log phase in nutrient broth and visually
standardized to a 0.5 McFarland turbidity tube before dilution. 5 x 10^ cells in 50 pL of
broth were added to an equal volume of peptide solution in sterile wells, and incubated
overnight. The MIC is the lowest concentration of peptide that completely inhibits
growth of the organism as detected by the unaided eye.
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2.4 Experimental
2.4.1 General Methods
The peptides were synthesized on a Milligen 9050 peptide synthesizer using
orthogonally protected amino acids. The a amines were protected using FMOC and the
e-amines on the lysines were protected with t-BOC.

The carboxylate ends of the

amino acids were activated as an OPfp ester. The resin used was PAL-PEG-PS and all
amino acids were weighed to have a 4 fold excess compared to the resin substitution
level. HPLC was conducted on a Waters 600E instrument. The analytical and prep
methods used a Waters C4 cartridge column while the prep fractions were checked
using a Vyadac C-18 column. The mobile phase was a gradient of double distilled
water and acetonitrile. CD concentration studies were carried out on a Aviv Model
62DS CD spectrometer. The pathlengths of the cells varied from 0.001 cm at high
concentration to 0.01 cm at lower concentrations.

All concentration studies were

carried out using 2.5mM potassium phosphate buffer pH= 7.45.
2.4.2 Solid Phase Peptide Synthesis
The procedure for the synthesis of a peptide via solid phase peptide synthesizer
follows a repetitive scheme. After the PAL-PEG resin is placed in a column, there is an
initial washing of the resin using DMF at 5mL/ min which cleans the resin/amino acid.
This is followed by a piperidine wash for lOmin at 5ml/min. Since piperidine is a base,
the purpose o f it is to remove the FMOC protecting group of the a-amine on the amino
acid anchored on the resin. After this step, the resin/peptide is washed again with DMF
for 12 min (at 5mL/min).

This needs to be done in order to insure that residual

piperidine is removed. While the resin is being washed, the next amino acid is being
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dissolved in DMF and 1-hydroxybenzotriazole (HOBT). The HOBT improves coupling
yields. The amino acid, after being dissolved in the DMF/HOBT, is delivered to the
resin where it is recycled through the resin for 1 hour. This is followed by an 8 minute
DMF wash to remove the excess amino acid present in the system. The above is
repeated until the peptide has been completed. After the final amino acid is placed on
the peptide, there is a 12 minute DMF wash at 5 mL/min and a 15 min DCM wash. At
this point the peptide/resin combination is taken off of the synthesizer and is manually
washed with MeOH in order to shrink the resin and it is filtered and dried in a high
vacuum desicator.

After drying the peptide is cleaved using reagent B. Reagent B is

made by combining 8.8 mL trifluoroacetic acid, 0.5 mL phenol, 0.5 mL water, 0.2 mL
of triisopropylsilane while bubbling Ar through the system.

This is added to the

peptide/resin and stirred for 4 hours and the mixture was filtered to remove the peptide
from the resin.

Again two methods were used to purify the peptide. In the first

method, the solution containing the peptide was dropped into cold diethyl ether where it
precipitated as a white solid. The diethyl ether is then placed into Corex tubes and
centrifuged at 7000 rpm for 20 minutes at 20°C in order to concentrate the peptide into a
pellet. The diethyl ether is poured off and allowed to evaporate. The crude peptide was
then dried overnight in a vacuum desicator. After drying, the peptide was dissolved in
0.1 M acetic acid and ran through a Sephadex G-15 column in 100 mg portions. This
removes residual organic molecules as well as small peptides which represent failed
sequences. The second method involves dissolving the peptide solution in 20% acetic
acid and extraction with diethyl ether. The peptide, in the aqueous solution, is frozen
and lyophilized. The cmde peptide is then further purified using HPLC.
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2.4.3 CD Studies
The CD instrument was purged with liquid nitrogen blow-off for 30 minutes
before starting. A series of solutions were made with concentrations varying from 40
mg/mL to 8 mg/mL. All solutions were prepared from a stock solution of -40 mg/mL
(this was subsequently corrected via amino acid analysis) using 2.5 mM sodium
phosphate buffer at pH=7.3. The pH of the buffered solution was subsequently checked
after the addition of the peptide. A CD spectrum was taken from 225 nm to 190 nm at
1 second per point sampling at every 0.5 nm with a bandwidth of 0.7 nm. Two scans o f
each solution were taken. The resultant milidegrees at 220 nm were converted to molar
ellipticity and graphed as a function of log of concentration of peptide in mM.
2.5 Conclusion:
This work demonstrates not only the importance of leucine zippers in
aggregation, but also the importance of the placement of the leucine zippers in the ahelical wheel. If not all three leucines are within the a-helical region of the peptide,
they will not be able to complete a proper leucine zipper. The result will be a peptide
which will have a decreased molar ellipticity due to a decrease in the stabilizing force of
the aggregation state which holds the peptide in an a-helical state.
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3.1 Uses of Pyrenylalanine
The excited state of pyrene has the unique property of having a high quantum
yield and a long lifetime. It also forms an excimer when two pyrenes are within 3 A
from one another due to the overlapping of the n orbitals. Because of this, it has been
used as a fluorescent probe. Since 1983, pyrenylalanine (figure 3.1.1) has been used to
probe the formation and behavior of peptides and polymer.
Sisido synthesized block polymers of pyrenylalanine with blocks of benzyl
glutamates in order to study the spectroscopic properties of the pyrenylalanines.29
Poly(y-benzyl dl-glutamate) solubilized the long pyrenylalanine polymer and was
studied using CD and fluorescence spectroscopy. Sisido observed tentative evidence
that the pyrenyl portion of the peptides arranged itself in a sandwich-like configuration.
Homochiral polymers showed reduced excimer formation while racemic polymer had
predominant excimer formation. He concluded that descreet arrangement of the peptides
reduced excimer formation. Sisido continued his work by doing a more detailed study
of the block copolymer of glutamate and pyrene. 30 Using advanced techniques, he
isolated the components of fluorescence to show where the excimer formation arises
from the random coil and from more ordered systems.
Pyrenylalanines have probed solvent affects on dipeptides.

De Schryver

synthesized w-acetyl-bis(pyrenylalanine)-methylester (both the erythro and threo
compounds) in order to determine how solvent effects the arrangement of random coiled
peptides. 31 He concluded that hydrogen donating solvents reduce the partial double
bond character of the peptide by hydrogen bridging with the solvent making the
dipeptides more structured. Hydrogen accepting solvents shifted the dipeptides to a
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Figure 3.1.1: Pyrenylalanine
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more random coil conformation by decreasing intramolecular hydrogen bonding. De
Schryver continued his work using both stationary and transient fluorescence techniques
to determine how dipeptides behaved in systems. 32 He concluded that the dipeptides
are stabilized through intramolecular hydrogen bond formation in the presence of
solvents which cannot form hydrogen bonds.
Pyrenylalanine has been used to investigate opiate receptors. In the mid ‘80s,
Costa published a series of papers in which pyrenylalanine was incorporated into the 4
or 5 position in [D-Ala2, D-Leu5]enkephalins (heretofore known as DADLE) and its
methyl ester. 33 The incorporation of pyrenylalanine made the modified DADLE five
times more selective for the 5-receptor. When pyrenylalanine replaced an essential Tyr1
in an enkephalin, the result showed the pyrenylalanine enkephalin bound to an opiate
receptor to a point o f inhibiting the Tyr 1-containing enkephalin. It is also noted that the
methyl ester derivative bound to the p. receptor than to the 5 receptor 24 fold more
strongly while the C-terminal free analogue of the pyrene enkephalin analogue showed
preference for a 5 receptor.

Incorporation of two pyrenylalanines into an enkephalin

analogue in the 1 and 4 or 5 position made the peptide unable to interact with the opiate
receptor.34
Another aspect of pyrenylalanine investigated involved the idea of photoinduced
electron transfer in a-helical backbones.35 In one paper, p-dimethylanilino acted as an
electron donor while pyrenylalanine acted as a photsensitizer with an alanine separating
the two groups and coupled to a copolymer of y-benyl-l-glutamate. The peptide showed
electron transfer between the donor and the pyrenylalanine.
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Other uses of pyrenylalanine involved the incorporation of it into chiral bilayer
membranes that had the property o f going from a gel phase to a liquid crystalline phase
at 35.2°C.36 The authors reported that, while in a gel phase the pyrenyl groups arranged
in such a way to prevent excimer formation while in the pyrenyl groups randomly
ordered in the liquid crystal phase.
Sannamu Lee incorporated pyrenylalanine into an amphipathic/antimicrobial
peptide to gain insight into the action of peptides on lipid bilayers. 37

The

photophysical results of the peptides interactions on bilayers appeared in a subsequent
paper.38 The amphipathic peptide contained a basic sequence of four amino acids;
namely, -L-Leu-L-Ala-L-Arg-L-Leu- in a four quadrad repeat called A4 . Three different
peptides incorporated the pyrenylalanine in the 5th, 7th, and 9th position while one
peptide incorporated two pyrenylalanines in the 5th and 9th position. Experiments on
these peptides included CD, fluorescent binding studies with DPPC and the authors
reported that the labeled peptides existed as a monomer in the liposome layer while as
an oligomer in an aqueous layer.

The

authors also did a quenching study of a

tryptophan labeled peptide in a DPPC bilayer and found that iodine did not quench the
tryptophan fluorescence. This led the authors to believe that the tryptophan embedded
into the nonpolar lipid bilayer while the rest of the peptide lies on the surface of the
bilayer. They further concluded that the nonpolar portion of the amphipathic peptide
interacted with the lipid bilayer.

The authors also observed via CD, that the

introduction o f the fluorescent side chains in the nonpolar region of the peptide could
induce peptide-peptide interactions.

This paper clearly demonstrated the use of

pyrenylalanine in investigating lipid-peptide and peptide-peptide interaction.
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Pyrenylalanine has been used to explore the interaction of two amphipathic ahelical peptides anchored by a bipyridyl group.39
pyrenylalanine

The peptides incorporated

in the nonpolar region at the interface between the Leu and Ala.

Circular dichroism monitored the

interaction of the peptides in both aqueous and

MeOH solvents. The authors noted that in an a-helical configuration, the pyrene groups
aligned themselves between the two a-helical peptides. MeOH induced a random coil
configuration and the pyrenes did not align themselves. A subsequent paper reported
further CD and fluorescent data appeared in another paper. 40 Here the authors give
evidence of excimer formation under aqueous conditions. The authors also did studies
of the denaturation of the covalently attached a-helical bundles using MeOH, heat and
guanidine HC1.

The covalently bundled peptides exhibited standard denaturation

characteristics as evidence through both CD and fluorescent studies. As the peptides
became more random coil, an absence of excimer formation occurred.
The use of pyrenylalanine as a fluorescent probe in covalently attached a-helical
bundles extended to a 4 covalently attached a-helical bundles. 41 This paper reported
both fluorescence and CD spectra. The result showed that the pyrenylalanine, properly
placed in the hydrophobic region of the peptide, resulted in excimer formation in
aqueous environments. Aqueous environments do promote a-helical structures. Using
MeOH as a solvent resulted in little if any excimer formation. The authors stated that
the peptide most likely formed a random coil in an MeOH environment and therefore
little if any excimer occurred.

The authors reported no other evidence that the 4

covalently attached a-helical bundle folded into a bundle structure.
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Finally, pyrene explored the nature of leucine zippers in an amphipathic peptide.
42

Garcia-Echeverria used pyrenebutyric acid to label a peptide within its leucine zipper

region. CD and fluorescence experiments showed the peptide formed a dimer in
aqueous conditions. The fluorescence occurred only if the peptide arranged itself in a
parallel dimer formation.
In conclusion the literature clearly shows the usefulness of pyrenylalanine and
pyrene products. Through various techniques which depend on the unique fluorescent
properties o f pyrene, many aspects of the peptides aggregation and structure comes to
light.
3.2 Methods for the synthesis of Pyrenylalanine
Various methods have been used to synthesize pyrenylalanine. One of the first
involved the formation of an oxalazone with hippuric acid and pyrene carboxaldehyde.
This was then hydrogenated and oxidized using phosphorous.

31

This was a racemic

mixture though and consequently they were used in this fashion. Figure 3.2.1 illustrates
the method for the synthesis of pyrenylalanine.
The most common method for the synthesis of pyrenylalanine is a variation of
the above. In this case, the pyrene oxalazone is ring opened using sodium ethoxide and
then resolved using (-)-l-phenylethylamine.
pyrenylalanine.

30

The result is enantiomercially pure

The number of steps in this procedure is six and because the product

has to be resolved, the yield on this set of reactions is poor. Figure 3.2.2 illustrates the
experimental procedure of this reaction.
Another method that has been used for the synthesis of pyrenylalanine involve
creating a template that would only allow the hydrogenation of the precursor
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enantionselectively. This molecule first involved the formation of a cyclic dipeptide of
glycine and alanine.

34

Chirality of the molecule is introduced with the alanine. The

methyl group of the alanine allows for only one face of the pyrene to associate with the
palladium. Because of this, only one side of the precursor will be hydrogenated making
this enantioselective. Figure 3.2.3 illustrates this reaction set.
Finally, a more interesting method has also been found to produce
pyrenylalanine. This involves the use of a acylase.

acetyl-DL-Pyrenylalanine was

produced using any method of choice. After this Aspergillus acylase was used to
deacetylate only the L-pyrenylalanine causing it to precipitate out of solution. This was
then collected and used in the experimentation. 40
3.3 Synthesis of Pyrenylalanine
The synthesis of pyrenylalanine gave us an opportunity to explore the area of
glycine templates. Glycine templates are molecules which have a chiral substituent that
cause an alkylation to the template to occur enantioselectiveiy. This method offers
superior enantioselectiveiy compared to methods which rely on resolution or one in
which hydrogenation is directed enantioselectivty. After alkylation, the removal of the
enantiomeric directing group is removed and the product is isolated. One such glycine
templates is (2R,3S)-(-)-6-oxo-l,4-morphiline-carboxylate or William’s template (see
figure 3.3.1). The alkylation is directed enantioselectivly by the two chiral phenyl
substituents. Once deprotonated, the glycine template will attack an alkyl halide via a
backside attack shown in figure 3.3.2.

R ep ro d u ced with p erm ission o f the copyright ow ner. Further reproduction prohibited w ithout perm ission.

49

oV

►

P y r- C

NaOOCCH

1)P, HI, (CH3C0)20
2) H20

HO
■NH-

(Racemic)

Figure 3.2.1: Synthesis o f racemic pyrenylalanine
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Attempted synthesis of pyrenylalanine was a modification of the procedure
presented in the literature.[William’s, 1990 #93]

It involved the following steps.

Alkylation of 1-bromomethylpyrene with (2R,3 S)-(-)-6 -oxo-1,4-morphiline-carboxyIate
was accomplished by first converting the template to the enolate using Na
bistrimethylsylyl amide and then reacting with 1-bromomethylpyrene. The Boc-group
was removed with the use of trimethylsilyliodine in an inert atmosphere. The reaction
was judged over in about 30minutes via TLC (mobile phase: 50% Hexane, 30%
Chloroform 20% Ethyl Acetate). The template was ring opened using 6 M HC1. Finally
the phenyl rings were to be removed using sodium periodate through oxidation of the
phenyl rings to benzaldehyde. Unfortunately, the final step of this reaction did not
occur possibility due to the insolubility of the starting material. The solvent conditions
for this reaction is THF/H2O adjusted to a pH of 3. As the reaction continued, the
starting material would precipitate. Figure 3.3.3 illustrates the reaction sequence using
William’s glycine template.
Another template attempted involved a template first synthesized by Seebach.

43

This uses the glycine template l-benzyl-2-r-butyl-3-methyl-4-imidazolidinones (see
figure 3.3.4). In this case, the enantioselectivity of the molecule is controlled by the
chiral terf-butyl group.

This molecule has the additional advantage of, when the

alkylation occurs, the enantioselectivity can be checked by NOESY NMR due to the
interaction of the a-proton with the protons on the terf-butyl group which is shown in
figure 3.3.5. After alkylation, the glycine template was hydrolized to remove the tertbutyl group and form the amino acid. Under various conditions attempted, this did not
occur. Figure 3.3.6 shows the reaction sequence using Seebach’s template.
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The failure of all these reactions did not occur in the alkylation, but in the final
step of the reaction involving the final formation of the amino acid. It was in the
hydrolysis step that failed in these sequences.

The reaction sequence that did work

used the glycine template invented by O’Donnel. In this template, the hydrolysis step
was very facile. Though the reaction does not go enantioselectiveiy, the product was
finally synthesized. Figure 3.3.7 illustrates the reaction sequence for the formation of
pyrenylalanine.
3.4 Incorporation of Pyrenylalanine into a peptide
The peptide chosen to incorporated the pyrenylalanine was H-(Lys,Leu,Ala,
Lys,Lys,LeurAia)3-NH2. The Alanine in the 14th position was replaced with the
pyrenylalanine. The synthesis of the peptide containing the pyrenylalanine was
accomplished by solid phase peptide synthesis as described in the previous chapter.
Purification of the peptide via HPLC was done under similar conditions as
described in the previous chapter. However, since the pyrenylalanine amino acid was
racemic, the peptide had to be purified enantiomercially. In order to explain how the
peptide was purified enantiomercially, one must understand how a C-4 column works.
The nonpolar regions of the peptide bind to the stationary phase of the column upon
initial conditions of the mobile phase which is, in this case 90:10 HiOtCHsCN. As the
nonpolar portion of the mobile phase increases, the peptide will then disassociate with
the stationary phase allowing it to come out purified.

Since different peptides are

unique, the percentage of polar/nonpolar mobile phase in which the peptide comes off is
also unique. Therefore peptides which contain amino acids that did not couple, and
therefore shorter than there parent peptide, will come off at a different time, called the

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

55

OH

2. dry DCM

.Br

Ph*. X .
+

O

^

1. Na Bisftrimethysilyl) amide

I

„
2 - TH F -78°C

1. Trimethylsilyl Iodide
2.

^

Ph

Ph

Ph^A-oH

" V ^ o

OH

HNv \ )

O

6N HC1/THF

Ph

PhyX-oH^

h 2n ^ (

OH

HN' ^ C

q

OH

l)N aI04
2) HC1/THF

Figure 3.3.3: Attempted Synthesis of Pyrenylalanine using William’s glycine template
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Figure 3.3.4: Seebach’s glycine template

CH

Figure 3.3.5: Alkylated Seebach’s glycine template demonstrating how NOESY
interactions are used to check the enantioselectivity of the reaction
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Figure 3.3.6: Attempted synthesis of Pyrenylalanine using Seebach’s Glycine template
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Figure 3.3.7: Synthesis of Pyrenylalanine via O’Donnel’s glycine template
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retention time, than the completed peptide. What is critical to this system is the actual
binding of the peptide to the column stationary phase. The mobile phase 90% H20/
10% Acetonitrile causes the peptide to assume an a-helical shape. In this particular
case, the peptide synthesized is a mixture containing one with an L-pyrenylalanine and
another with a D-pyrenylalanine. When these peptide are a-helical, the one containing
the D-pyrenylalanine, is bent as compared to the one containing the L-pyenylalnine.
This cause the peptide with the D-pyrenylalanine to have different binding efficiencies
than the one with the L-Pyrenylalanine.

Therefore the retention time of the D-

pyrenylalanine containing peptide will be slightly less than the L-pyrenylalanine
containing peptide.

This fact was exploited in order to purify the peptides

enantiomerically.
3.5 CD and Fluorescence studies of pyrene containing peptide
As the peptides form an a-helical shape, they will tend to aggregate.

The

question arised as to whether they aggregate parallel or antiparallel to one another. With
a pyrenylalanine in the 14th position on the peptide, if the peptides aligned in an
antiparallel fashion, then the pyrene may be in close enough proximity to cause the
formation of excimer. If the peptides aggregated in an parallel fashion, the pyrenes
would not be close enough to form an excimer thus showing no such evidence in the
fluorescent studies. The peptide (Lys,LeurAla,Lys,Lys,Leu,Ala)3 was used as a model
peptide in order to get the solvent conditions appropriate for the peptide containing the
fluorescent probe. After incorporation of the fluorescent probe, an absorbance was
taken in order to determine if the probe was within the structure and also to determine
the concentration of the peptide in various experiments completed (see figure 3.5.1).
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The absorbance of the pyrene in the peptide is characteristic of other pyrene containing
peptides noted in the literature.
All CD and fluorescent studies were completed in 2.5mM tris buffer. This was
done due to a better behavior of peptides in Tris buffer as opposed to phosphate buffer.
As stated, the CD’s o f the peptides were done on with (LysJLeurAla,Lys,Lys,LeurAla)3
acting as a model compound. The object of one of the experiments was to find the best
solvent conditions for the peptides to exist in an a-helical shape. Figure 3.5.2 shows
the CD of the fluorescently labeled peptide in 1M NaCl in tris buffer. The graph is
reported in molar ellipticity. Using the formula discussed in the previous chapter, the
helicity of the peptide is 81.49%. This affords a good helicity for the peptide to study
the possible interactions of the pyrenes in an aggregated state.
Fluorescent study of the peptide was carried out on an SLM model fluorimeter
utilizing magic angle. Again this was carried out in 2.5mM tris buffer with 1M NaCl at
pH=7.42 using a 35 pL capillary ceil. A second study was also carried out in 2.5mM
tris buffer without NaCl. Both spectra are shown as figures 3.5.3 and 3.5.4. The peptide
is not in an a-helical state without the salt and at these concentrations. Because it is not
in an a-helical state, it will not be aggregated in an ordered state. Therefore one can
see if there is a difference in the fluorescence between an ordered stated and a
nonordered state of peptides.
The fluorescent spectra represented here show the emission spectra when the
peptide was excited at different wavelengths. A difference can clearly be seen between
both spectra when the peptide was excited at 330 nm. In the system which contained
the 1M NaCl, there is a definite tailing in the spectra while the system containing the no
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Figure 3.5.1: Absorbance spectra of labeled peptide
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Figure 3.5.2: CD spectra of labeled peptide
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Figure 3.5.3. Emission spectra of labeled peptide 1 M NaCl. ------, 315 nm excitation;
, 330 nm excitation;
, 345 nm excitation;
365 nm excitation;
400
nm excitation.
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Figure 3.5.4: Emission spectra of labeled peptide 0 M NaCl. ----- , 330 nm excitation;
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NaCl there is no such tailing.

Because it is being excited at 330 nm, which is

considered a low wavelength with pyrene, this is indicative of a ground state emission.
Usually in pyrene, a molecule is first excited and then an emission is observed. This
excitation is seen when the molecule is excited at wavelengths higher than 365 nm.
3.6: Experimental
3.6.1: Synthesis o f 1-bromomethylpyrene

The synthesis of 1-bromomethylpyrene followed a procedure found in a paper
by Akiyama with a slight modification.44 5.0 g (0.02 mol) of pyrenemethanol was
dissolved in 100ml o f dry dichloromethane, under Argon, and cooled to 0°C. To this
solution was added 0.0908 mL (0.0112 mol) of pyridine. 1.76 mL (0.0187 mol) of
PBr3 was dissolve in dry dichloromethane and added to the pyrenemethanol over a
period of 20 minutes. The reaction was then allowed to go overnight. The reaction was
then placed in a separatory funnel and cooled double distilled water was added. The
organic layer was subsequently washed with water, aqueous sodium bicarbonate and
water. The organic layer was then dried with sodium sulfate, filtered and rotovapped.
The solid 1-bromomethylpyrene was collected as a yellow powder in an 85% yield; m.p.
141°C; lit m.p. 131-133°C; 1HNMR(200Mhz, CDCl3) 5.25(s,2H) 8.00-8.57(m,9H).

3.6.2:

Synthesis

of

(3R,5R,6S)-4-(fert-ButoxycarbonyI)-2,3,5,6-tetrahydro-3-

pyrenyl-5,6-diphenyl-l,4-oxazin-2-one.

1.36 g (0.0075 mol) of sodium bis(trimethylsilyl)amide was dissolved in dry
THF under Argon and cooled to -78°C using a dry ice/acetone. To this was added
slowly in a dropwise fashion, 2.39 g (0.0068 mol) of (3R,5R,6S)-4-(tert-
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Butoxycarbonyl)-2,3,5,6-tetrahydro-5,6-diphenyl-l,4-oxazin-2-one dissolved in dry
THF. After 20 minutes of stirring, 2.0 g (0.0068 mol) of bromomethylpyrene dissolved
in dry THF was added dropwise to the above solution and was allowed to stir overnight.
Double distilled water was added to the system in order to destroy excess base still
present in the system. The product was extracted with diethyl ether and dried over
anhydrous sodium sulfate. TLC (mobile phase: 50:30:20 Hexane/Chloroform/Ethyl
Acetate) revealed two spots at Rf 0.7 and 0.85. The solvent was removed and the
product was recrystallized in refluxing acetonitrile. yield 90%; !H NMR (200MHz,
CDCl3) 1.04(s,9H) 3.54(d,lH) 3.92(d, 1H) 4.08(d, 1H) 4.41(d, 1H) 5.49(d, 1H)
5.87(d,lH) 6.25(d 1H) 6.8-6.94 (m, 10H) 7.7-8.3(m, 9H)

3.6.3:

Synthesis

o f (3R,5R,6S)-2,3,5,6-tetrahydro-3-pyrenyI-5,6-diphenyI-l,4-

oxazin-2-one

This reaction follows closely the procedure published by Williams45 without
modifications. 2.0

g (0.0035 mol) of (3R,5R,6S)-4-(tert-Butoxycarbonyl)-2,3,5,6-

tetrahydro-3-pyrenyI-5,6-diphenyI-l,4-oxazin-2-one

was

dissolved

in

dry

dichloromethane and stirred under argon. To this was added 1.72 g (0.0085 mol) of
trimethylsilyl iodide and stirred for 30 minutes. The reaction was then quenched with
15 mL of water and extracted with dichloromethane. The combined organic layers were
washed with 1M sodium thiosulfate. The organic layers were then dried with anhydrous
sodium sulfate and rotovapped. Yield 92%; lH NMR (200MHz, C D C I 3) 3.77-3.87 (dd,
1H) 4.27-4.33(dd, 1H) 4.50-4.56(dd, 1H) 4.90(d, 1H) 5.29(dd, 1H) 6.8-7.25(m, 10H)
7.78-8.47 (m, 10H)
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3.6.4: Synthesis o f N-(l,2-dibenzyl-ethan-2-ol)-pyrenylalaiiine

This followed closely the procedure of Williams.45 1.5 g (0.0030 mol) of
(3R,5R,6S)-2,3,5,6-tetrahydro-3-pyrenyl-5,6-diphenyl-l,4-oxazin-2-one was dissolved
in a mixture of 25 mL o f THF and 50 of 10% HC1 and allowed to stir overnight. This
was then rotovapped under high vacuum. Yield 95%;

lH NMR (200 MHz, DMF-cU)

2.78-2.95 (dd, 1H) 3.7-3.S (dd, 1H) 4.8(d, 1H) 6.86-7.18(m, 10H) 7.99-8.37 (m, 10H)

3.6.5: Attempted synthesis o f Pyrenylalanine

1.45 g (0.0028

mol) of N-(l,2-dibenzyl-ethan-2-ol)-pyrenylalanine was

dissolved in 25mL of THF. 1.33 g (0.0062 mol) of sodium periodate was dissolved in
45 mL double distilled water adjusted to pH=3 and added to the N-(l,2dibenzyl-ethan2-ol)-pyrenylalanine solution. This was allowed to stir for three days. After this the
flask had a white precipitate which NMR revealed to be starting material.

3.6.6:

Synthesis

of

(2S,5R)-l-benzoyl-2-ter/-butyI-5-pyenyl-3-methyI-4-

imidazolidinone

1.3

mL of 1.5 M LDA was dissolved in THF and placed in a flask under argon and

cooled to -78°C using an acetone/dry ice bath. 0.34 g (0.0013 mol) of (2S)-l-benzoyl2-te/Y-butyl-3-methyl-4-imidazolidinone was dissolved in dry THF and slowly injected
into the flask and allowed to stir for 20 minutes.

0.35

g (0.0012

mol) of

bromomethylpyrene was dissolved in dry THF and slowly injected into the mixture.
After 10 minutes the, the dry ice bath was taken away and the system was allowed to stir
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for 2 hours. The reaction was then quenched with double distilled H2O. The reaction
system was then extracted with diethyl ether, dried over anhydrous sodium sulfate and
the solvent was removed. Recrystallization was accomplished in ethyl acetate to give a
white solid in a 67% yield; m.p. 87°C; *H NMR (200MHz, CDCI3) 1.01 (s, 9H) 2.98(s,
3H) 3.47(s, 1H) 3.85(s, 1H) 4.91-4.93(d, 1H) 5.61(s, 1H) 7.25-7.38(m, 5H) 7.888.15(m, 9H)

3.6.7: Attempted synthesis o f Pyrenylalanine

0.075 g (0 .0002 mol) of (2S,5R)-l-benzoyl-2-rer/-butyl-5-pyenyl-3-methyl-4imidazolidinone was dissolved in 6 M HClrglacial acetic acid. This was refluxed at
110°C for 20 hours. NMR revealed starting material.

3.6.8: Synthesis of Schiffbase-ferf-butoxypyrenylalanine

0.27 g (0.0015 mol) of sodium bis(trimethylsilyi)amide was dissolved in dry THF
under argon and cooled to -78°C with an acetone/dry ice bath. 0.44 g (0.0015 mol) of
terf-Butylglycinate Schiff base was dissolved in dry THF and slowly injected into the
solution.

This was allowed to stir for 20 minutes.

0.4

g (0.0014

mol) of

bromomethylpyrene was dissolved in THF and then slowly injected into the system.
This was allowed to stir overnight. The reaction was then quenched with double
distilled H2O, extracted with diethyl ether, dried over anhydrous sodium sulfate and the
solvent was removed. Yield 72%; lH NMR (200 MHz, CDC13) 1.48 (s, 9H) 3.75-3.84
(dd, 1H) 4.01-4.07 (dd, 1H) 4.44-4.49 (dd, 1H) 6.07 (d, 1H) 6.66-7.50 (m, 10H) 7.88.17 (m, 9H)
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3.6.9: Synthesis o f Pyrenylalanine
1.1

g (0 .0 0 2 2 mol) of Schiffbase-terr-butoxypyrenylalanine was dissolved in

THF. To this was added a catalytic amount of triisopropylsilane to act as a carbocation
scavenger.

6

N HC1 was added and an immediate color change was noted. TLC noted

one spot Rf =0.0 with a positive ninhydrin test. 1:1 glacial acetic acid:con HC1 was
added and the mixture was extracted with diethyl ether.

The aqueous layer was

evaporated overnight to reveal a white crystalline product.

This was dissolved in

95%EtOH and, upon neutralization with propylene oxide, a white precipitate formed.
65% yield; *H NMR (200MHz, DMSO-dfi) 3.33-3.55 (m, 2 H) 4.07-4.12 (d, 1H) 7.988.47 (m, 9H)

3.6.10: Synthesis o f Fmoc-Pyrenylalanine

0.15 g (0.0005 mol) of pyrenylalanine was dissolved in 1:2 solution of
10 %Na2CC>3:

Dioxane. 0.192 g (0.0006 mol) of fluorenylmethylcarbonyl sucinimide

was directly added to the solution while stirring. The pH of the solution was adjusted to
8

with the slow addition of triethyl amine and the solution was allowed to stir for 30

minutes. The solution was then filtered and then acidified using 1 mol HC1 causing a
white precipitate to fall out of solution. This precipitate was filtered and dried in a
vacuum descicator overnight. TLC (9:1 CHCLiMeOH) has one spot at Rf= 0.2.Yield
82%; *H NMR (200MHz, DMSO-de) 3.5-3.62(t, 1H) 3.93-4.15(m, 2H) 4.43(t, 1H)
7.11-7.85 (m, 8 H), 8.02-8.47 (m, 9H)
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3.7: Conclusion
The fluorescently labeled peptide was modeled on Sybyl on an Silicon Graphics
Onyx workstation in order to determine how the pyrenes would align when the peptides
aggregate in either parallel or antiparallel. If the peptides are aligned in a parallel
fashion, the pyrenes would not be in proximity to one another to form an excimer in
either a ground or excited state. When the peptides aggregate in an antiparallel fashion,
then the pyrenes will align to be able to form an excimer in a ground or an excited state.
In fact, the distance between the two pyrenes in an antiparallel aggregation state is
between two and six angstoms. However, in the computation study, the peptides were
placed in an aggregated state and not aggregated computationally and the aggregated
peptides were not minimized.
In conclusion, the placement of one fluorescent probe in a peptide has given a
wealth of information. The absorbance spectra showed that the probe was actually
placed in the peptide and was used to give an accurate measurement of the
concentration of the peptide via Beer’s law. The CD spectra of the labeled peptide is
the similar to those without a fluorescent label. This is due to the presence of the
pyrenylalanine. It also shows that the pyrenylalanine is within the a-helical portion of
the peptide. Through solving of the equation mentioned in chapter 2, we found that the
peptide is 81% a-helical. Finally by looking at the fluorescence spectra. There shows
ground state excimer formation which can only occur when the peptides are aggregated
in an antiparallel fashion.
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